Wells Fargo Rates GeneDx Overweight, Retains $155 Target After 50% Plunge
Wells Fargo upgraded GeneDx to Overweight from Equal Weight on February 9, upheld its $155 target after the stock fell over 50% since December. GeneDx delivered Q4-2025 revenue of $121M (+32% YoY) and projected 33–35% revenue growth in 2026 to $540–555M, highlighting new prenatal test and expanded sales team.
1. Wells Fargo Upgrade
On February 9, Wells Fargo raised GeneDx’s rating to Overweight from Equal Weight while keeping the $155 target price unchanged, attributing the move to the stock’s steep price decline rather than any new company developments.
2. Stock Performance and Financials
GeneDx’s share price has fallen more than 50% since December and is down about 30.8% year-to-date; the company reported Q4-2025 revenue of $121 million, up 32% year-over-year, and full-year 2025 revenue of $427 million, a 54% increase.
3. 2026 Guidance and Catalysts
Management expects 2026 revenue growth of 33–35% to $540–555 million and identified an expanded sales force, entry into new markets, a phenotype-informed prenatal test launch, and a partnership with Komodo Health as key catalysts in the latter half of the year.